Imaxio and VitamFero announce the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio’s pro-immunogenic technology, and VitamFero’s live attenuated parasites, for vaccines development.
VitamFero is a biotechnology firm in the Genopole cluster with a secondary facility in Tours (Indre & Loire, France) that develops novel veterinary and human vaccines against parasitic diseases. It announced filing of a new patent to cover the very good results obtained with its vaccine candidate against human ocular toxoplasmosis.
On January 10th 2013, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London.
VitamFero has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal parasites.